The FDA cleared Embryo Predict, an AI-powered embryo assessment tool developed by Alife Health, making it the first commercially available AI embryo assessment platform for Day 5-7 blastocysts to receive FDA clearance. The decision was supported by prospective, randomized, multicenter clinical evidence involving 440 patients across seven U.S. fertility clinics, giving the tool a stronger evidentiary basis than much of the AI embryo-grading software already in informal use at IVF clinics nationwide.
The Problem Embryo Predict Targets
In vitro fertilization has long relied on embryologists visually grading embryos under a microscope to decide which one is most likely to result in a successful pregnancy, a process that is inherently subjective and can vary from lab to lab and even from one embryologist to another within the same clinic. With IVF costing patients tens of thousands of dollars per cycle and success far from guaranteed, even small improvements in embryo selection accuracy carry significant financial and emotional weight for patients undergoing fertility treatment.
What Made This Clearance Different
AI-assisted embryo grading tools have already become widely used in fertility clinics over the past several years, but most have lacked the kind of rigorous, prospective, randomized clinical trial data that regulators typically require for higher-confidence claims. Embryo Predict’s 440-patient, seven-clinic randomized trial gives it a distinctive evidentiary foundation, and clinical research cited in fertility industry publications has pointed to improvements in implantation rates, reduced miscarriage rates and more accurate prediction of live birth chances associated with AI-assisted embryo selection more broadly.
How AI Embryo Grading Works
These systems analyze time-lapse images and video of developing embryos, tracking cell division timing, morphology and other developmental markers that correlate with implantation success, then ranking embryos by predicted viability. The goal is to give embryologists an additional, more consistent data point beyond visual assessment alone, particularly useful in cases involving multiple viable-looking embryos where the choice of which to transfer first carries real consequences for a patient’s treatment timeline and cost.
Points of Debate in the Fertility Field
Some reproductive endocrinologists have welcomed AI-assisted embryo selection as a long-overdue source of standardization in a field that has relied heavily on subjective visual assessment for decades. Others in the fertility community caution that even sophisticated algorithms are working from indirect, structural cues rather than direct genetic or chromosomal information, and note that AI ranking should complement, not replace, established techniques like preimplantation genetic testing when appropriate. There are also ongoing questions about cost, since AI embryo selection tools typically add to the already substantial expense of an IVF cycle, raising equity concerns about whether the technology will primarily benefit patients who can already afford advanced fertility care.
Part of a Broader IVF Technology Wave
Embryo Predict’s clearance is part of a broader transformation underway in fertility medicine in 2026, as AI tools move from research settings into mainstream treatment at leading fertility clinics, alongside advances in robotics and other automation technologies reshaping IVF lab workflows more generally. A February 2026 study specifically evaluated the stability and reliability of various AI models used for embryo selection and ranking, reflecting growing scientific scrutiny of how consistent these tools are across different clinical settings and embryo populations.
What’s Next
Alife Health says it plans to expand Embryo Predict’s deployment across more fertility clinics following the FDA clearance, and further studies are expected to track long-term outcomes, including live birth rates, among patients whose treatment incorporated the AI tool. As the fertility industry continues to embrace AI-assisted decision-making, Embryo Predict’s rigorous trial data could set a new evidentiary bar that other embryo-grading software vendors are pushed to match.
The Emotional and Financial Stakes of Every Transfer
For couples undergoing IVF, each embryo transfer typically costs thousands of dollars on top of the emotional toll of waiting to learn whether a cycle succeeded, stakes that explain why even incremental improvements in embryo selection accuracy generate such strong interest across the fertility industry. Patient advocacy groups have generally welcomed Embryo Predict’s rigorous trial data as a reassuring sign that regulators are holding AI fertility tools to a higher evidentiary bar than the informal grading software many clinics had already adopted without comparable randomized trial evidence behind it. Fertility clinics that have already adopted Embryo Predict say they plan to track live birth outcomes over the coming year to build a real-world evidence base beyond the original 440-patient trial, data that regulators and patients alike are expected to watch closely.
